NFL, NFLPA Launch Joint Review of Jalen Hurts Blood Clot Diagnosis as Eagles Futures Collapse

The NFL and the NFL Players Association are working together to review how Philadelphia Eagles quarterback Jalen Hurts’ blood clot diagnosis was handled, the two sides said in a joint statement Sunday. The announcement comes five days after the union called for a full investigation into the medical care Hurts received, and it adds another layer of uncertainty to an Eagles season that has already tilted sharply in the futures market.

Hurts was placed on injured reserve and is expected to miss the rest of the 2026 season after a blood clot in his left calf traveled to his lungs. The Eagles and his agent, Nicole Lynn, said Monday that he has deep vein thrombosis and bilateral pulmonary emboli. He is being treated with blood thinners and cannot take part in any football activities until he is off them. The team said he is clinically stable and is expected to make a full recovery.

What the NFL and NFLPA Are Reviewing

The timeline is at the center of the dispute. Hurts was cut by a cleat on his calf in an Oct. 4 game against the Los Angeles Rams and told the medical staff about the injury after practice on Oct. 8. Specialists in London initially diagnosed a superficial vein thrombosis in his left calf before the Eagles’ Week 5 game against the Jacksonville Jaguars on Oct. 11. He played in that game, throwing for 220 yards and a touchdown, and the team flew home afterward. By the time he was back in the United States, the clot had moved, and the Eagles placed him on injured reserve on Oct. 17.

The NFLPA said last week that it was not aware of any league investigation and that the NFL had previously told the union it did not plan to review Hurts’ care. "Before conclusions are drawn about how this situation was handled, there must be a full investigation into what occurred," the union said. Commissioner Roger Goodell said Wednesday that the league welcomes a probe, adding that the protocols were followed. NFL chief medical officer Dr. Allen Sills defended the Eagles’ medical staff at the league meetings, saying a bad outcome does not prove a flawed process and that everyone involved was "incredibly conservative and incredibly vigilant." Sills also noted that the league tracks blood clot cases every year and shares the data with the union.

Sunday’s statement suggests the two sides are pursuing a cooperative review for now rather than a unilateral union investigation. Head coach Nick Sirianni has said the decision to play Hurts was left to the team’s medical experts. No findings or timeline for the review have been announced.

On the Field: Tanner McKee Takes Over a 2-4 Team

Hurts finishes the year having completed 57.8 percent of his passes for 933 yards, eight touchdowns and three interceptions across five games, with 107 rushing yards and a rushing touchdown. Backup Tanner McKee made his first start of the season in a 25-14 loss to the Carolina Panthers, going 26 of 45 for 215 yards and a touchdown. Philadelphia sits at 2-4, second in an NFC East where the New York Giants lead at 3-2-1 and the Dallas Cowboys are also 2-4.

The Eagles host Dallas on Monday Night Football at Lincoln Financial Field with McKee under center again. The offense has been one of the league’s weakest, averaging 173.3 passing yards per game, 26th in the NFL, and 17.7 points per game, tied for 28th.

Betting Market Impact: Eagles Futures Take the Hit

The futures market has already priced in a lost season. According to Sports Illustrated’s odds coverage, Philadelphia’s Super Bowl price dropped from +4000 to +15000 over the two weeks after Hurts’ injury came to light, and the Eagles were listed at +460 to make the playoffs. DraftKings moved Philadelphia to +550 to win the NFC East, which made the Eagles the fourth-best price in the division. Other books list the Eagles even longer for the title, with BetMGM showing them at +20000 and FanDuel at +12500, a reminder that prices vary by book and move frequently.

Prediction markets tell a similar story. Kalshi had the Eagles priced at roughly a 12 percent chance to win the NFC East and a 15 percent chance to reach the playoffs, with Super Bowl and NFC championship odds below 1 percent. With the division so compressed, the Eagles are not entirely out of the race, but the market is treating the loss of Hurts as the end of any serious title push.

The quarterback swap is also showing up in the game lines. Philadelphia is a 4 to 4.5-point home underdog against a Cowboys team with the same 2-4 record, with Kalshi giving Dallas a 64 percent win probability. The Eagles are 1-5 against the spread this season, while the Cowboys are 3-3. That is a notable shift for a team that opened the year as a top-five Super Bowl contender in the futures market.

Looking ahead, the review itself is unlikely to move Eagles odds directly, since Hurts is out regardless of what it finds. Its market relevance is indirect: any findings about the timeline of his diagnosis and clearance could shape league policy on how soft-tissue and vascular injuries are handled, which in turn could affect how bettors and oddsmakers treat questionable-status quarterbacks in the future. For now, the Eagles’ season outlook rests on McKee, a banged-up offense and a division that remains wide open.